Toronto Dominion Bank boosted its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 6.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,884 shares of the medical equipment provider’s stock after buying an additional 1,741 shares during the period. Toronto Dominion Bank owned approximately 0.06% of ABIOMED worth $12,987,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ABMD. NEXT Financial Group Inc bought a new position in ABIOMED in the 3rd quarter valued at $115,000. TRUE Private Wealth Advisors bought a new position in ABIOMED in the 3rd quarter valued at $162,000. OLD Mutual Customised Solutions Proprietary Ltd. bought a new position in ABIOMED in the 2nd quarter valued at $164,000. Rampart Investment Management Company LLC bought a new position in ABIOMED in the 2nd quarter valued at $175,000. Finally, NewSquare Capital LLC bought a new position in ABIOMED in the 2nd quarter valued at $186,000. 84.88% of the stock is currently owned by institutional investors.

In other news, VP Andrew J. Greenfield sold 4,440 shares of the stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total transaction of $1,753,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of the stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the transaction, the vice president now directly owns 48,954 shares in the company, valued at approximately $21,172,605. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.

Several equities analysts have commented on ABMD shares. ValuEngine downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Morgan Stanley raised ABIOMED from an “equal” rating to a “weight” rating and upped their price objective for the company from $396.00 to $496.00 in a research report on Wednesday, November 7th. BidaskClub downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective on the stock in a research report on Friday, November 2nd. Finally, Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $402.78.

ABMD opened at $299.83 on Tuesday. ABIOMED, Inc. has a 12-month low of $186.72 and a 12-month high of $459.75. The firm has a market cap of $14.40 billion, a PE ratio of 122.38, a PEG ratio of 2.61 and a beta of 0.35.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.36. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business had revenue of $181.78 million for the quarter, compared to the consensus estimate of $175.41 million. During the same quarter in the prior year, the company earned $0.54 EPS. The business’s revenue was up 36.9% compared to the same quarter last year. On average, research analysts forecast that ABIOMED, Inc. will post 3.57 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/20/toronto-dominion-bank-buys-1741-shares-of-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: Do You Need a Fiduciary?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.